{
    "root": "0e87ba50-9918-4733-8ed3-95ce3c772b07",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "LOTEPREDNOL ETABONATE",
    "value": "20250521",
    "ingredients": [
        {
            "name": "LOTEPREDNOL ETABONATE",
            "code": "YEH1EZ96K6",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31784"
        },
        {
            "name": "BENZALKONIUM CHLORIDE",
            "code": "F5UM2KM3W7",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3020"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13404"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "TYLOXAPOL",
            "code": "Y27PUL9H56",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_141517"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "loteprednol etabonate ophthalmic suspension indicated treatment steroid responsive inflammatory conditions palpebral bulbar conjunctiva , cornea anterior segment globe allergic conjunctivitis , acne rosacea , superficial punctate keratitis , herpes zoster keratitis , iritis , cyclitis , selected infective conjunctivitides , inherent hazard steroid accepted obtain advisable diminution edema inflammation . loteprednol etabonate ophthalmic suspension less effective prednisolone acetate 1 % two 28-day controlled acute anterior uveitis , 72 % patients treated loteprednol etabonate ophthalmic suspension experienced resolution anterior chamber cells , compared 87 % patients treated prednisolone acetate 1 % . incidence patients clinically significant increases iop ( \u2265 10 mmhg ) 1 % loteprednol etabonate ophthalmic suspension 6 % prednisolone acetate 1 % . loteprednol etabonate ophthalmic suspension used patients require potent corticosteroid indication . loteprednol etabonate ophthalmic suspension also indicated treatment post-operative inflammation following ocular surgery .",
        "doid_entities": [
            {
                "text": "allergic conjunctivitis (DOID:11204)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11204"
            },
            {
                "text": "conjunctivitis (DOID:6195)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6195"
            },
            {
                "text": "acne (DOID:6543)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6543"
            },
            {
                "text": "rosacea (DOID:8881)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8881"
            },
            {
                "text": "punctate keratitis (DOID:12197)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12197"
            },
            {
                "text": "keratitis (DOID:4677)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4677"
            },
            {
                "text": "herpes zoster (DOID:8536)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8536"
            },
            {
                "text": "herpes zoster keratitis (DOID:8839)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8839"
            },
            {
                "text": "iritis (DOID:1406)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1406"
            },
            {
                "text": "anterior uveitis (DOID:1407)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1407"
            },
            {
                "text": "uveitis (DOID:13141)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13141"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute anterior uveitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_280886"
            }
        ]
    },
    "contraindications": {
        "text": "shake vigorously using . steroid responsive disease treatment : apply one two drops loteprednol etabonate ophthalmic suspension conjunctival sac affected eye ( ) four times daily . initial treatment within first week , dosing may increased , 1 drop every hour , necessary . care taken discontinue therapy prematurely . signs symptoms fail improve two days , patient re-evaluated ( ) . post-operative inflammation : apply one two drops loteprednol etabonate ophthalmic suspension conjunctival sac operated eye ( ) four times daily beginning 24 hours surgery continuing throughout first 2 weeks post-operative period .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "loteprednol etabonate ophthalmic suspension , 0.5 % sterile , white off-white uniform suspension essentially free foreign particles filled 10 ml 15 ml low density polyethylene white opaque bottle low density polyethylene white opaque nozzle high density polyethylene pink cap . available follows : 5 ml 10 ml bottle ( filled 1/2 capacity ) : ndc 60219-1362-1 10 ml 15 ml bottle ( filled 2/3 capacity ) : ndc 60219-1362-2 15 ml 15 ml bottle : ndc 60219-1362-3 storage : store upright 15\u00b0 25\u00b0c ( 59\u00b0 77\u00b0f ) . freeze . keep reach children . rx manufactured : amneal pharmaceuticals pvt . ltd. ahmedabad 382213 , india distributed : amneal pharmaceuticals llc bridgewater , nj 08807 rev . 05-2025 version-00",
    "adverseReactions": "loteprednol etabonate ophthalmic suspension , ophthalmic corticosteroids , contraindicated viral diseases cornea conjunctiva including epithelial herpes simplex keratitis ( dendritic keratitis ) , vaccinia varicella also mycobacterial infection eye fungal diseases ocular structures . loteprednol etabonate ophthalmic suspension also contraindicated individuals known suspected hypersensitivity ingredients preparation corticosteroids .",
    "indications_original": "Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.\n                  Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (\u2265 10 mmHg) was 1% with loteprednol etabonate ophthalmic suspension and 6% with prednisolone acetate 1%. Loteprednol etabonate ophthalmic suspension should not be used in patients who require a more potent corticosteroid for this indication.\n                  Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery.",
    "contraindications_original": "SHAKE VIGOROUSLY BEFORE USING.\n                  \n                     Steroid Responsive Disease Treatment: Apply one to two drops of loteprednol etabonate ophthalmic suspension into the conjunctival sac of the affected eye(s) four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see \n                        PRECAUTIONS\n                     ).\n                  \n                     Post-Operative Inflammation: Apply one to two drops of loteprednol etabonate ophthalmic suspension into the conjunctival sac of the operated eye(s) four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.",
    "warningsAndPrecautions_original": "Loteprednol Etabonate Ophthalmic Suspension, 0.5% is a sterile, white to off-white uniform suspension essentially free from foreign particles filled in 10 mL or 15 mL low density polyethylene white opaque bottle with low density polyethylene white opaque nozzle and high density polyethylene pink cap.\n                  It is available as follows:\n                  5 mL in 10 mL Bottle (Filled to 1/2 Capacity):\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 60219-1362-1\n                  10 mL in 15 mL Bottle (Filled to 2/3\u00a0Capacity):\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 60219-1362-2\n                  15 mL in 15 mL Bottle:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 60219-1362-3\n                  \n                  \n                     Storage: Store upright between 15\u00b0 to 25\u00b0C (59\u00b0 to 77\u00b0F). DO NOT FREEZE.\n                  \n                     KEEP OUT OF THE REACH OF CHILDREN.\n                  \n                  \n                     Rx only\n                  \n                  Manufactured by: \n                  \n                     Amneal Pharmaceuticals Pvt. Ltd.\n                  \n                  Ahmedabad 382213, INDIA \n                  Distributed by: \n                  \n                     Amneal Pharmaceuticals LLC \n                  \n                  Bridgewater, NJ 08807 \n                  Rev. 05-2025\n                  Version-00",
    "adverseReactions_original": "Loteprednol etabonate ophthalmic suspension, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Loteprednol etabonate ophthalmic suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.",
    "drug": [
        {
            "name": "LOTEPREDNOL ETABONATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31784"
        }
    ]
}